discovery and research Lead Optimization IND-Enabling Phase 1 azp-3601 azp-3404 azp-38xx


AZP-3601: Hypoparathyroidism

AZP-3601 is a peptide analog of parathyroid hormone (PTH) that targets a specific configuration of the PTH1 receptor to safely produce sustained levels of calcium in the blood and thereby control the symptoms of hypoparathyroidism.1

AZP-3601 has been designed to prevent chronic kidney disease by limiting the amount of calcium eliminated in the urine, and to preserve bone integrity, an important benefit since a large proportion of patients with hypoparathyroidism are middle-aged women often at an increased risk of developing osteoporosis.

AZP-3601 has already demonstrated an optimal pharmacological profile in several preclinical studies.2,3 We have successfully completed pre-investigational new drug activities and a Phase 1 clinical study has been initiated in September 2020.


AZP-3404 is the first therapeutic peptide to leverage the biology of insulin-like growth factor binding protein 2 (IGFBP2), and to utilize multiple, well-established pathways to restore the body’s regulation of fat and glucose metabolism.

IGFBP2 is a protein that carries out the actions of leptin, a hormone that regulates fat and glucose metabolism. The ability of IGFBP2 to do this resides in a small peptide sequence within its structure. AZP-3404 is a stabilized peptide analog of this sequence and is the first drug candidate to reproduce and utilize the unique biology of IGFBP2.4,5,6

We are currently conducting pre-investigation new drug activities and exploring target indications for AZP-3404.

insulin like growth factor binding protein 2

AZP-38XX: Acromegaly

AZP-38XX Acromegal

Amolyt Pharma is currently testing a series of novel, small peptide antagonists of the growth hormone (GH) receptor to select a lead development candidate for treatment of acromegaly, under a research collaboration with Peptidream. Acromegaly is a rare disease characterized by abnormally high levels of GH, which in turn causes excess production of insulin-like growth factor-1 (IGF-1). By preventing the interaction between GH and its receptor, the antagonist peptides are expected to normalize the excess IGF-1 in patients with acromegaly. To date, there have been over 140 peptides designed from the originally discovered GH antagonist peptide, and that have been optimized to provide greater potency and efficacy.

Scroll to Top